| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 04/21/2005 | US20050085758 Dilute aqueous solution containing epidermal growth factor in gel |
| 04/21/2005 | US20050085711 Method and system for leading macromolecule substances into living target cells |
| 04/21/2005 | US20050085552 Method for providing long-lasting pain relief through intrathecal administration of civamide |
| 04/21/2005 | US20050085542 Solution for peritomeal dialysis |
| 04/21/2005 | US20050085498 a lipid soluble thiamine such as benfotiamine, creatine ethyl ester for example; reducing serum glucose levels and maintaining those reduced glucose levels over time to treat diabetic polyneuropathy, improving circulation |
| 04/21/2005 | US20050085485 Parkinson's disease; mixing with lactose and starches |
| 04/21/2005 | US20050085471 Using 2-morpholinyl-4H-pyrido(1,2-a)pyrimidin-4-one; enzyme inhibitors; antithrombotic agents ; restenosis; atherosclerosis; antihistamines; chronic obsessive pulminary disease; autoimmune diseases; anticancer agents; antiinflammatory agents |
| 04/21/2005 | US20050085462 Solid oral formulation coated with hydroxypropyl methylcellulose; the polymer coating is free of polyethylene glycol |
| 04/21/2005 | US20050085450 Oral antidepressant formulation |
| 04/21/2005 | US20050085448 Viricides against herpes virus; autoimmune disease; antitumor agents |
| 04/21/2005 | US20050085446 bactericial composition for topical application to the eye containing a soluble polymer to reduce the precipitation of the bactericide on the cornea; particularly a fluoroquinolone, a steroidal or non-steroidal anti-inflammatory agent, cyclodextrin, a hydroxy acid and water with a pH between 4.5 and 7. |
| 04/21/2005 | US20050085445 Mixture containing hydrophilic additive; measured dosage aerosol inhaler |
| 04/21/2005 | US20050085440 Formulation |
| 04/21/2005 | US20050085434 Ballast administering to human skins; dna vaccine; high density core overcoated with amorphous reservoir containing dna |
| 04/21/2005 | US20050085431 Treatment of hypertension |
| 04/21/2005 | US20050085430 Phosphodiesterase-4 (PDE4) inhibitor such as roflumilast or cilomilast; low amounts of active agents, less prone to detrimental side effects |
| 04/21/2005 | US20050085426 Acid-sensitive compounds, preparation and use thereof |
| 04/21/2005 | US20050085415 Nanoparticles injected directly into eye; integrin receptor antagonist; angiogenesis inhibitor, polypeptide |
| 04/21/2005 | US20050084966 Methods for inducing the differentiation of blood monocytes into functional dendritic cells |
| 04/21/2005 | US20050084608 Surface treatment; nanomaterial containing core and cladding; heat treatment |
| 04/21/2005 | US20050084553 Composition containing moutan root bark extract as active ingredient |
| 04/21/2005 | US20050084549 Fiber rich fraction of Trigonella Foenum-graceum seeds and its use as a pharmaceutical excipient |
| 04/21/2005 | US20050084541 Oral micropellets containing an antibiotic having an inner coating of a cellulose polymer (not enteric)and an outer coating of an enteric coating polymer; particle size of 100 to 650 mu m.; lack of bitter taste; fast dissolution; increased antibiotic bioavailability compared pellets having a matrix |
| 04/21/2005 | US20050084540 Taste masking antibiotic composition |
| 04/21/2005 | US20050084538 Ultrasonic concentration of drug delivery capsules |
| 04/21/2005 | US20050084537 Sustained-release compositions |
| 04/21/2005 | US20050084536 Treating a microparticle dispersion by filtration, particularly by tangential flow filtration, in a closed circuit under aseptic conditions to obtain a filtrate and a retentate; collecting the retentate; continuous processing; particle diameters of 10nm-500mu m;kidney dialysis; hollow fiber dialyzer |
| 04/21/2005 | US20050084535 Novel calixarene based dispersible colloidal systems in the form of nanoparticles |
| 04/21/2005 | US20050084534 Delivery of physiological agents with in-situ gels comprising anionic polysaccharides |
| 04/21/2005 | US20050084533 Polymer composite with internally distributed deposition matter |
| 04/21/2005 | US20050084532 Contacting a polymer substrate with a plasticising fluid comprising a liquid or gaseous fluid in its natural or supercritical state to plasticize or swell the polymer to incorporate mammalian, plant and bacterial subcellular, cellular or multicellular matter, liposomes; drug delivery; surgery; grafting |
| 04/21/2005 | US20050084531 A tablet core of highly water-soluble active ingredient, e.g.,potassium chloride having an aqueous-based, dried coating of ethyl acrylate-methyl methacrylate copolymer of 0.5%-1.17% by weight after a greatly shortened drying time (30 minat 50 degrees C.); stable release profile; solvent-free; efficiency |
| 04/21/2005 | US20050084530 Rapid acting freeze dried oral pharmaceutical composition for treating migraine |
| 04/21/2005 | US20050084529 Oral bioavailability; protease inhibitors with water soluble polymer and surfactant |
| 04/21/2005 | US20050084527 Pharmaceutical formulations containing combinations of epinastine, pseudoephedrine, and methylephedrine |
| 04/21/2005 | US20050084526 Preparing a self-dispersing or self-emulsifying immediate-release tablet by compressing microgranules of a lipophilic drug with nonswellable fillers and tabletting aids with an oil, and a surfactant of fatty acid triglycerides, fatty acid-polyoxyethylene glycol or a polar liquid; bioavailability |
| 04/21/2005 | US20050084525 Method for blinding a medication |
| 04/21/2005 | US20050084523 Inhaling formulation providing analgesia to patient; contains one rapid-onset opioid and a sustained-effect opioid; avoiding toxicity while achieving analgesia, side effect occurs before the onset of toxicity; dispensers |
| 04/21/2005 | US20050084522 Cationic lipids for nuclei acid delivery |
| 04/21/2005 | US20050084521 A non-aqueous adhesive layer on a side of the support and comprising an adhesive and a vaporizable antimicrobial agent; antimicrobial adhesive sheet has a moisture permeability of at least 1,000 g/m2*24 hrs; exerts the antimicrobial activity not only on an attached site but also in the space by the site |
| 04/21/2005 | US20050084520 Method for providing long-lasting pain diminishment through topical or intranasal administration of civamide |
| 04/21/2005 | US20050084516 Process for making gel films |
| 04/21/2005 | US20050084513 Nanocoating for improving biocompatibility of medical implants |
| 04/21/2005 | US20050084506 Amide compounds such as (R)-methyl 2-(3-chloro-4-methoxybenzamido)-4-methylpentanoate and urea compounds such as 1-(2-chlorophenyl)-3-(heptan-4-yl)urea for modulating taste of food or drug products |
| 04/21/2005 | US20050084482 As an antiinflammatory agent for gastrointestinal inflammation involved with inflammatory bowel disease or irritable bowel syndrome |
| 04/21/2005 | US20050084470 Anionic surfactants, seed oil microparticles and a moisturizer; moisturization with concurrent exfoliation |
| 04/21/2005 | US20050084458 Solution or dispersion of lipophilic dialkyl diselenide such as dihexyl diselenide in a carrier for topical use |
| 04/21/2005 | US20050084457 Capsules for inhalation made from specific capsule materials such as a mixture of cellulose derivatives, starch, starch derivatives, chitosan and synthetic plastics, reduced moisture content, containing tiotropium salt in the form of powdered preparations; stability |
| 04/21/2005 | US20050084456 Functionalized particles |
| 04/21/2005 | US20050084455 Two anti-tuberculosis drugs, and a biodegradable polymer such as polylactic acid, polyglycolic acid, lactic acid-glycolic acid copolymer, polycaprolactone, polysebacic anhydride in dosage form |
| 04/21/2005 | US20050084454 A quaternary ammonium salt as an active agent and a pharmaceutically acceptable carrier suitable for intranasal delivery, formulated to reduce odors without triggering non-allergic rhinitis when delivered intranasally |
| 04/21/2005 | US20050084453 Mixing a sterol or a polyether modified phospholipid capable of forming a liposome with a supercritical carbon dioxide, contacting water-soluble nonionic iodine compound with phospholipid to form a liposome containing vesicles including the iodine compound; chlorine-free solvent |
| 04/21/2005 | CA2785138A1 Rapidly disintegrating formulation |
| 04/21/2005 | CA2542474A1 Medicament on the basis of honey, preparation and use thereof |
| 04/21/2005 | CA2542295A1 Method |
| 04/21/2005 | CA2542288A1 Chimeric promoter comprising hcmv major immediate early gene exons and a heterologous intron |
| 04/21/2005 | CA2542099A1 Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| 04/21/2005 | CA2541811A1 Drug-delivery vehicles based on reversed liquid crystalline phase materials |
| 04/21/2005 | CA2541578A1 Sustained-release microgranules containing gingko biloba extract and the process for manufacturing these |
| 04/21/2005 | CA2541382A1 A solid dosage form comprising a fibrate and a statin |
| 04/21/2005 | CA2541371A1 Extended release formulations of opioids and method of use thereof |
| 04/21/2005 | CA2540582A1 Screening method for evaluation of bilayer-drug interaction in liposomal compositions |
| 04/21/2005 | CA2540301A1 A dried biotherapeutic composition, uses, and device and methods for administration thereof |
| 04/21/2005 | CA2540042A1 Aerosol formulation comprising formoterol in suspension |
| 04/21/2005 | CA2540038A1 Aerosol formulations comprising formoterol fumarate dihydrate, a propellant,ethanol and optionally a steroid,where the formoterol fumarate dihydrate has a water content of 4.8-4.28% by weight |
| 04/21/2005 | CA2539872A1 Compositions for conjugated estrogens and associated methods |
| 04/21/2005 | CA2538362A1 Water dispersible film |
| 04/21/2005 | CA2538104A1 Use of xenon with hypothermia for treating neonatal asphyxia |
| 04/21/2005 | CA2538099A1 Pharmaceutical multiparticulate composition comprising mycophenolic acid or mycophenolate sodium and combination with rapamycin |
| 04/21/2005 | CA2537315A1 Protein biomaterials and biocoacervates and methods of making and using thereof |
| 04/21/2005 | CA2532837A1 Method for preparing small spherical particles by controlled phase separation |
| 04/20/2005 | EP1524029A1 Self-Emulsifying Compositions |
| 04/20/2005 | EP1523998A2 Antimicrobial adhesive sheet and antimicrobial method using the same |
| 04/20/2005 | EP1523994A1 Medicinal composition for regulating release and process for producing the same |
| 04/20/2005 | EP1523993A1 Polypeptide compositions with improved stability |
| 04/20/2005 | EP1523984A1 Pharmaceutical composition comprising oxoplatin, salts and derivatives thereof |
| 04/20/2005 | EP1523983A1 Pharmaceutical composition comprising fenofibrate and process for its preparation |
| 04/20/2005 | EP1523981A1 Extended release formulations of venlafaxine |
| 04/20/2005 | EP1523979A1 Extended release pharmaceutical dosage form |
| 04/20/2005 | EP1523978A2 Crystalline forms of pravastatin sodium |
| 04/20/2005 | EP1523977A1 Multilamellar coalescence vesicles (MLCV) containing biologically active compounds |
| 04/20/2005 | EP1523976A2 Pharmaceutical formulations of salmeterol |
| 04/20/2005 | EP1523975A2 Pressurised metered dose inhalers (MDI) |
| 04/20/2005 | EP1523974A1 Composition for rapid disintegrating tablet in oral cavity |
| 04/20/2005 | EP1523489A2 Modified 2' and 3' -nucleoside produgs for treating flaviridae infections |
| 04/20/2005 | EP1523486A2 Tetracyclic arylsulfonyl indoles having serotonin receptor affinity |
| 04/20/2005 | EP1523367A1 Microneedle devices and microneedle delivery apparatus |
| 04/20/2005 | EP1523354A1 Administration device comprising an osmotic drive |
| 04/20/2005 | EP1523336A1 Targeted agents for nerve regeneration |
| 04/20/2005 | EP1523335A2 Injectable depot formulation comprising crystals of iloperidone |
| 04/20/2005 | EP1523330A2 Vaccine against salmonid rickettsial septicaemia based on arthrobacter cells |
| 04/20/2005 | EP1523325A2 Methods and compositions for treating polycystic ovary syndrome |
| 04/20/2005 | EP1523319A1 Method for sustaining direct cell delivery |
| 04/20/2005 | EP1523305A2 Device and patch for controlling the release of vanillin |
| 04/20/2005 | EP1523304A1 Oral care capsules |
| 04/20/2005 | EP1523303A1 Medicaments containing vardenafil hydrochloride trihydrate |
| 04/20/2005 | EP1523302A2 Method for producing crystals from active ingredients in medicaments, crystals obtained therefrom and the use thereof in pharmaceutical formulations |
| 04/20/2005 | EP1523301A2 Delivery system for pharmaceutical agents |
| 04/20/2005 | EP1523287A2 Materials with both bioadhesive and biodegradable components |
| 04/20/2005 | EP1523239A1 Use of a composition and a cleaning tablet containing said composition for disinfecting purposes |